{"id":10845,"date":"2025-09-26T23:09:01","date_gmt":"2025-09-26T23:09:01","guid":{"rendered":"https:\/\/cannabisindustryjournal.com\/?post_type=feature_article&amp;p=37486"},"modified":"2025-09-26T23:09:01","modified_gmt":"2025-09-26T23:09:01","slug":"an-inside-look-at-germanys-cannabis-supply-chain-with-the-grunhorn-group","status":"publish","type":"post","link":"https:\/\/cannitrol.com\/blog\/an-inside-look-at-germanys-cannabis-supply-chain-with-the-grunhorn-group\/","title":{"rendered":"An Inside Look at Germany\u2019s Cannabis Supply Chain With The Gr\u00fcnhorn\u00a0Group"},"content":{"rendered":"<div id=\"wp_fb_like_button\" style=\"margin:5px 0 5px 5px;float:right;height:100px;\"><script src=\"http:\/\/connect.facebook.net\/en_US\/all.js#xfbml=1\"><\/script><fb:like href=\"https:\/\/cannitrol.com\/blog\/an-inside-look-at-germanys-cannabis-supply-chain-with-the-grunhorn-group\/\" send=\"true\" layout=\"standard\" width=\"450\" show_faces=\"false\" font=\"arial\" action=\"like\" colorscheme=\"light\"><\/fb:like><\/div><p><span data-preserver-spaces=\"true\">On April 1, 2024, Germany launched Pillar 1 of its adult-use legalization framework, building on its established medical cannabis program that has been in place since 2017. Since then, the number of medical patients has surged, as prescriptions remain the only fully legal access point for cannabis aside from home cultivation or membership in non-commercial private clubs, both still limited by incomplete regulations. Unlike the United States, where dispensaries are the backbone of cannabis sales, Germany maintains a more tightly regulated model: patients must secure a doctor\u2019s prescription and fulfill it through a pharmacy.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">The next stage, Pillar 2, is expected to introduce licensed retail outlets for adult-use sales, eliminating the requirement for prescriptions. However, with the Christian Democratic Party now in office and maintaining a strong stance against cannabis legalization, these plans face significant uncertainty. While advocates remain hopeful for progress, the CDU\u2019s opposition could delay, restrict, or even reverse parts of the rollout, leaving the future of Germany\u2019s adult-use market in question.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">In the meantime, Germany is laying the groundwork for a national infrastructure rooted in its medical system, a stark contrast to the fragmented, state-by-state patchwork in the U.S. This centralized approach not only offers greater oversight and consistency but also positions Germany as a potential model for other European nations exploring reform.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">At the center of this rapidly evolving landscape is the Gr\u00fcnhorn Group, one of the country\u2019s most influential players. With an estimated 20 percent market share serving between 5\u20137 million patients in a nation of 84 million, Gr\u00fcnhorn has established a vertically integrated<img loading=\"lazy\" class=\"size-full wp-image-37488 alignright\" src=\"https:\/\/cannitrol.com\/blog\/wp-content\/uploads\/2025\/09\/an-inside-look-at-germanys-cannabis-supply-chain-with-the-grunhorn-group.jpg\" alt=\"\" width=\"200\" height=\"200\" \/> supply chain that spans importing biomass from global producers, EU-GMP-certified manufacturing, and robust distribution networks. Beyond production, the company operates Germany\u2019s largest online pharmacy platform, giving patients access to products from multiple manufacturers. According to Matthias Fischer, Managing Director of Canymed, Gr\u00fcnhorn\u2019s distribution partner, the group generated \u20ac33 million in revenue in 2024, provided medicine to approximately 60,000 patients, and engaged with nearly 6,000 prescribing physicians.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Prioritizing Data Collection for Medical Research\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/span><\/strong> <span data-preserver-spaces=\"true\">For Gr\u00fcnhorn, data is at the core of both its medical mission and its business strategy. The company systematically collects patient feedback on the effects of its products\u2014whether for sleep, anxiety, focus, or other conditions\u2014to inform evidence-based product development. This feedback loop allows Gr\u00fcnhorn to collaborate closely with cultivation partners in designing strains that balance cannabinoids and terpenes to address specific therapeutic needs.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Beyond patient-level insights, Gr\u00fcnhorn is also investing heavily in analytical research. The company operates a gas chromatograph to precisely measure and map the cannabinoid and terpene composition of imported biomass, creating a detailed strain database. To date, Gr\u00fcnhorn has cataloged between 400 and 500 strains of interest, providing one of the most comprehensive genetic and chemical libraries in Germany\u2019s cannabis sector.<\/span><\/p>\n<blockquote>\n<p><span data-preserver-spaces=\"true\">\u201cI think the future lies in predicting and knowing which cannabinoids will effectively address specific health indications,\u201d says Fischer, underscoring the company\u2019s long-term vision of turning raw data into targeted, science-driven therapies.<\/span><\/p>\n<\/blockquote>\n<p><strong><span data-preserver-spaces=\"true\">Germany is an Import Market<\/span><\/strong><\/p>\n<p><span data-preserver-spaces=\"true\">While Germany has licensed domestic cultivation, led by producers such as Tilray, Demecan, and Aurora, the country remains heavily dependent on imports. According to Fischer, the quality of German-grown cannabis has not yet reached the standards set by established cultivation markets in Canada, Portugal, Denmark, and Colombia. To maintain product consistency and meet patient expectations, Gr\u00fcnhorn partners with a Canadian grower, underscoring the ongoing importance of international supply in Germany\u2019s cannabis ecosystem.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Economic factors also weigh heavily on domestic production. High energy costs make large-scale cultivation within Germany particularly challenging, pushing wholesale prices above those of imported flower. As a result, most of the market is supplied by international partners who can cultivate at scale more efficiently and deliver the product at a lower cost.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">This reliance on global supply chains is not unique to Gr\u00fcnhorn.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Cantourage, one of Germany\u2019s largest medical cannabis manufacturers, has built its strategy around imports, maintaining partnerships with 40 cultivators across 17 countries. Together, these dynamics reinforce Germany\u2019s role as one of the world\u2019s largest import-driven cannabis markets, even as it develops its own infrastructure.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Bottlenecks in the Pharmacy System<\/span><\/strong><\/p>\n<p><span data-preserver-spaces=\"true\">Germany\u2019s pharmacy network, spanning both retail and online channels, remains the cornerstone of cannabis dispensing in the country. As patient demand surges, many traditional pharmacies have launched digital platforms to streamline order management. Gr\u00fcnhorn has leaned into this shift, expanding its online pharmacy delivery while forging partnerships with local pharmacists who see cannabis as a valuable revenue driver.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Yet the system is under strain. Because only licensed pharmacists can legally fulfill prescriptions, they often face capacity challenges. Compounding, bottling, labeling, and testing must still<\/span> <span data-preserver-spaces=\"true\">be performed<\/span> <span data-preserver-spaces=\"true\">manually, creating bottlenecks in day-to-day operations. To keep pace, some pharmacists pre-produce standardized products based on everyday patient needs, despite the model being designed for on-demand compounding. Recognizing these inefficiencies, Gr\u00fcnhorn is investing in custom machinery and software solutions to help pharmacists scale production without compromising compliance, while maintaining oversight of quality and safety.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Another hurdle is product consistency. With prescriptions filled at thousands of independent pharmacies, often by third-party providers, slight variations in formulation are inevitable. \u201cIt\u2019s like having 6,000 different factories manufacturing your product,\u201d Fischer explains. To address this, Gr\u00fcnhorn is working on standardized fulfillment models to align independent pharmacies with the quality benchmarks already set by its own online platform.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">To further streamline the process, Gr\u00fcnhorn has integrated telemedicine into its supply chain. Patients can now connect directly with physicians, obtain prescriptions, and submit them seamlessly for fulfillment. This innovation helps address a recurring frustration: doctors inadvertently prescribing products that are out of stock, despite having access to inventory databases, ultimately reducing delays and ensuring patients remain on consistent treatment plans.<\/span><\/p>\n<p><strong><span data-preserver-spaces=\"true\">Partnerships and Opportunities<\/span><\/strong><span data-preserver-spaces=\"true\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Gr\u00fcnhorn\u2019s pharmacy data reveals that 20-30 percent of products generate 80 percent of revenue, indicating a potential for future product consolidation, according to Fischer. For investors, this presents an opportunity to fund medical brands with proven track records that are poised for growth and expansion<\/span><span data-preserver-spaces=\"true\">.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">In addition to producing its wholesale product line, Gr\u00fcnhorn is well-positioned and equipped to assist other brands looking to enter the German marketplace and welcomes co-branded product partnerships. They forged<\/span> <span data-preserver-spaces=\"true\">a partnership<\/span> <span data-preserver-spaces=\"true\">with Somai Pharmaceuticals, based in Portugal, resulting in a two-year, \u20ac10 million manufacturing and distribution deal.<\/span><\/p>\n<p><span data-preserver-spaces=\"true\">Fischer also believes AI will play a significant role in managing the industry in the future, suggesting an opportunity for those looking to enter the German market through technological innovation.<\/span><\/p>\n<blockquote>\n<p><span data-preserver-spaces=\"true\">\u201cThe biggest challenge we must overcome in the next couple of years is to generate data and medical studies,\u201d Fischer emphasizes. \u201cWe have many products with nice ideas, interested patients, and qualifying physicians, but we need more studies and proven evidence to present to new doctors and insurance companies, who are still challenging cannabinoid therapy and requesting data studies.\u201d<\/span><\/p>\n<\/blockquote>\n<div class=\"sharedaddy sd-sharing-enabled\">\n<div class=\"robots-nocontent sd-block sd-social sd-social-icon-text sd-sharing\">\n<h3 class=\"sd-title\">Share this:<\/h3>\n<\/p><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>On April 1, 2024, Germany launched Pillar 1 of its adult-use legalization framework, building on its established medical cannabis program that has been in place since 2017. Since then, the number of medical patients has surged, as prescriptions remain the only fully legal access point for cannabis aside from home cultivation or membership in non-commercial [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[8459,7814,5062,52,8509,8769,8461,5179,8503,8458,8770,5777,8564,10789,1964,5334,2254,5763,8514,8771,6431,9,8504,8471,8554,8472,1,3,61,1736],"tags":[8481,7815,5063,2632,8535,8779,8483,5181,8529,8480,8780,5783,8586,10792,4532,5350,4821,5771,8540,8781,6434,8530,8493,8576,8494],"_links":{"self":[{"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/posts\/10845"}],"collection":[{"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/comments?post=10845"}],"version-history":[{"count":0,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/posts\/10845\/revisions"}],"wp:attachment":[{"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/media?parent=10845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/categories?post=10845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cannitrol.com\/blog\/wp-json\/wp\/v2\/tags?post=10845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}